Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.73 0.71 (5.91%) Market Cap: 558.63 Mil Enterprise Value: 452.90 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 56/100

Q4 2021 Y-mAbs Therapeutics Inc Earnings Call Transcript

Feb 25, 2022 / 02:00PM GMT
Release Date Price: $8.91 (+11.24%)
Operator

Good day, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the Fiscal Full Year of 2021. Today's conference is being recorded.

Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties that are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's annual report on Form 10-K for the fiscal year ended December 31, 2021, as filed with SEC on February 24, 2022.

At this time, I would like to turn the conference over to Thomas Gad, the company's Founder, Chairman and President. Please go ahead.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President and Head of Business Development & Strategy

Thank you, Joe, and thank you,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot